236 related articles for article (PubMed ID: 19772888)
1. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.
Ma AC; Fan A; Ward AC; Liongue C; Lewis RS; Cheng SH; Chan PK; Yip SF; Liang R; Leung AY
Exp Hematol; 2009 Dec; 37(12):1379-1386.e4. PubMed ID: 19772888
[TBL] [Abstract][Full Text] [Related]
2. The role of jak2a in zebrafish hematopoiesis.
Ma AC; Ward AC; Liang R; Leung AY
Blood; 2007 Sep; 110(6):1824-30. PubMed ID: 17545503
[TBL] [Abstract][Full Text] [Related]
3. Jak2a regulates erythroid and myeloid hematopoiesis during zebrafish embryogenesis.
Zhu X; Liu R; Guan J; Zeng W; Yin J; Zhang Y
Int J Med Sci; 2017; 14(8):758-763. PubMed ID: 28824311
[TBL] [Abstract][Full Text] [Related]
4. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
6. Suppressor of cytokine signaling 1 regulates embryonic myelopoiesis independently of its effects on T cell development.
O'Sullivan LA; Noor SM; Trengove MC; Lewis RS; Liongue C; Sprigg NS; Nicholson SE; Ward AC
J Immunol; 2011 Apr; 186(8):4751-61. PubMed ID: 21421851
[TBL] [Abstract][Full Text] [Related]
7. Gene duplication of zebrafish JAK2 homologs is accompanied by divergent embryonic expression patterns: only jak2a is expressed during erythropoiesis.
Oates AC; Brownlie A; Pratt SJ; Irvine DV; Liao EC; Paw BH; Dorian KJ; Johnson SL; Postlethwait JH; Zon LI; Wilks AF
Blood; 1999 Oct; 94(8):2622-36. PubMed ID: 10515866
[TBL] [Abstract][Full Text] [Related]
8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
9. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
11. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
12. Zebrafish Jak2a plays a crucial role in definitive hematopoiesis and blood vessel formation.
Sung JJ; Jeon J; Lee JJ; Kim CG
Biochem Biophys Res Commun; 2009 Jan; 378(3):629-33. PubMed ID: 19059211
[TBL] [Abstract][Full Text] [Related]
13. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
[TBL] [Abstract][Full Text] [Related]
14. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.
Kubovcakova L; Lundberg P; Grisouard J; Hao-Shen H; Romanet V; Andraos R; Murakami M; Dirnhofer S; Wagner KU; Radimerski T; Skoda RC
Blood; 2013 Feb; 121(7):1188-99. PubMed ID: 23264594
[TBL] [Abstract][Full Text] [Related]
16. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
Duek A; Lundberg P; Shimizu T; Grisouard J; Karow A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2014 Jun; 123(25):3943-50. PubMed ID: 24820309
[TBL] [Abstract][Full Text] [Related]
17. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
18. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.
Lippert E; Boissinot M; Kralovics R; Girodon F; Dobo I; Praloran V; Boiret-Dupré N; Skoda RC; Hermouet S
Blood; 2006 Sep; 108(6):1865-7. PubMed ID: 16728702
[TBL] [Abstract][Full Text] [Related]
19. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera is not initiated by JAK2V617F mutation.
Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
